[go: up one dir, main page]

WO2002036769A3 - Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques - Google Patents

Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques Download PDF

Info

Publication number
WO2002036769A3
WO2002036769A3 PCT/EP2001/012495 EP0112495W WO0236769A3 WO 2002036769 A3 WO2002036769 A3 WO 2002036769A3 EP 0112495 W EP0112495 W EP 0112495W WO 0236769 A3 WO0236769 A3 WO 0236769A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
methods
nucleic acids
acids encoding
chimeric polypeptides
Prior art date
Application number
PCT/EP2001/012495
Other languages
English (en)
Other versions
WO2002036769A2 (fr
Inventor
Frank Dicker
Dirk Moritz
Gerd Maass
Original Assignee
Hoffmann La Roche
Frank Dicker
Dirk Moritz
Gerd Maass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Frank Dicker, Dirk Moritz, Gerd Maass filed Critical Hoffmann La Roche
Priority to AU2002221780A priority Critical patent/AU2002221780A1/en
Publication of WO2002036769A2 publication Critical patent/WO2002036769A2/fr
Publication of WO2002036769A3 publication Critical patent/WO2002036769A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un acide nucléique codant un polypeptide chimérique CD40/CD40L comprenant des fragments d'acide nucléique codant i) le domaine de signalisation de CD40 et en aval de celui-ci, ii) un domaine transmembranaire d'un récepteur de type II et en aval de celui-ci, iii) le domaine de liaison et de trimérisation de CD40L, cet acide nucléique pouvant être utilisé comme agent de thérapie génique pour le traitement local de tumeurs solides.
PCT/EP2001/012495 2000-10-31 2001-10-29 Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques WO2002036769A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002221780A AU2002221780A1 (en) 2000-10-31 2001-10-29 Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00123721 2000-10-31
EP00123721.3 2000-10-31

Publications (2)

Publication Number Publication Date
WO2002036769A2 WO2002036769A2 (fr) 2002-05-10
WO2002036769A3 true WO2002036769A3 (fr) 2003-01-30

Family

ID=8170257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012495 WO2002036769A2 (fr) 2000-10-31 2001-10-29 Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques

Country Status (2)

Country Link
AU (1) AU2002221780A1 (fr)
WO (1) WO2002036769A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739073C2 (ru) * 2014-04-07 2020-12-21 Локон Фарма Аб Новые медицинские агенты и их применение

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
EP2933334B1 (fr) 2003-02-18 2019-09-18 Baylor College of Medicine Activation induite dans des cellules dendritiques
EP2517723B1 (fr) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions et procédés d'amélioration des réponses immunitaires
AU2007310946B2 (en) 2006-10-19 2014-06-05 Baylor College Of Medicine Generating an immune response by inducing CD40 and pattern recognition receptors
EP2214840B1 (fr) 2007-10-30 2015-05-06 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer les réponses immunitaires dirigées contre une bactérie flagellée
CA3156538C (fr) 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions et procedes pour amplifier des reponses immunitaires a l'eimeria
DK2331680T3 (en) 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
WO2011146862A1 (fr) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Méthodes d'induction d'une apoptose sélective
JP5746333B2 (ja) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー カンピロバクター感染を減少させるワクチン及び方法
EP3610887B8 (fr) 2013-02-14 2024-01-24 The Board of Trustees of the University of Arkansas Compositions et procédés pour renforcer des réponses immunitaires vis-à-vis d'eimeria ou limiter une infection par eimeria
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
SG11201506974XA (en) 2013-03-14 2015-10-29 Bellicum Pharmaceuticals Inc Methods for controlling t cell proliferation
KR102239207B1 (ko) 2013-03-15 2021-04-09 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
CN106132423B (zh) 2014-02-14 2020-07-31 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
CA2959168A1 (fr) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation de recepteurs d'antigenes chimeriques par des polypeptides derives de myd88 et cd40
JP6718444B2 (ja) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） Ｂｏｂ１に対して指向されるＴ細胞レセプターおよびその使用
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US11564944B2 (en) 2016-11-21 2023-01-31 Nant Holdings Ip, Llc Fractal combination therapy
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
CA3098498A1 (fr) * 2018-06-14 2019-12-19 Nantbio, Inc. Proteines de fusion ligand-recepteur du type tnf et methodes associees
US20210369825A1 (en) * 2018-10-05 2021-12-02 Nantcell, Inc. Cd40 and cd40l combo in an adv vaccine vehicle
AU2020315796A1 (en) * 2019-07-19 2022-02-24 Memorial Hospital For Cancer And Allied Diseases Fusion polypeptide for immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (fr) * 1991-10-25 1993-04-29 Immunex Corporation Nouvelle cytokine
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1998026061A2 (fr) * 1996-12-09 1998-06-18 University Of California Nouveaux vecteurs d'expression contenant des genes de ligands de molecules accessoires et leur emploi a des fins d'immunomodulation et de traitement des tumeurs malignes et des maladies autoimmunes
WO2000063395A1 (fr) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (fr) * 1991-10-25 1993-04-29 Immunex Corporation Nouvelle cytokine
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1998026061A2 (fr) * 1996-12-09 1998-06-18 University Of California Nouveaux vecteurs d'expression contenant des genes de ligands de molecules accessoires et leur emploi a des fins d'immunomodulation et de traitement des tumeurs malignes et des maladies autoimmunes
WO2000063395A1 (fr) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739073C2 (ru) * 2014-04-07 2020-12-21 Локон Фарма Аб Новые медицинские агенты и их применение

Also Published As

Publication number Publication date
WO2002036769A2 (fr) 2002-05-10
AU2002221780A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
WO2002036769A3 (fr) Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques
WO2001072957A3 (fr) Molecules de type facteur de croissance des fibroblastes et leurs utilisations
EP1482040A3 (fr) Homologue NL6 du ligand du récepteur de kinase TIE
WO2002024891A3 (fr) Molecules semblables a b7 (b7-like, b7-l) et utilisations correspondantes
WO2002008285A3 (fr) Molecules il-17 et leurs utilisations
AU2175597A (en) Modulators of tnf receptor associated factor (traf), their preparation and use
IL140938A (en) Dna sequences encoding polypeptides capable of binding to ldcam, polypeptides encoded by them, fusion proteins comprising the polypeptides and a process for the preparation of the polypeptides
WO2001092308A3 (fr) Polypeptides a noeud de cystines: molecules 'cloaked-2' et leurs utilisations
WO2000018914A3 (fr) NOUVEAUX POLYPEPTIDES $i(DKR)
IL144952A0 (en) Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2003020932A1 (fr) Nouvelles proteines de secretion et adn associe
WO2001068854A3 (fr) Molecules s'apparentant au facteur de croissance des fibroblastes et leurs utilisations
WO2001055178A3 (fr) Compositions et methodes de traitement de cancer
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2001005825A3 (fr) Nouveaux procedes et materiaux des angiopoietines
WO2001068859A3 (fr) Molecules du type recepteur de l'interleukine 17 et leur utilisation
WO2003008446A1 (fr) Polypeptides se rapportant au transfert de signaux de recepteur de produits terminaux a glycation avancee
WO2001068705A3 (fr) Molecules du type recepteur de l'interleukine 17 et leurs utilisations
MXPA01006006A (es) Cadena receptora de citocina.
WO2001042474A3 (fr) Molecules de type interferon et utilisations
WO2002062954A3 (fr) Modulation antisens de l'expression de la caseine kinase 2-beta
WO2001019861A3 (fr) Anticorps du recepteur d'apo-2
WO2002016611A3 (fr) Polypeptides d'interleukine-22, acides nucleiques codant pour lesdits polypeptides et methode permettant de traiter les affections pancreatiques
WO2002062818A3 (fr) Modulation antisens de l'expression de la caseine kinase 2-alpha
WO2001059120A3 (fr) Molecules de type il-17 et utilisation de ces dernieres

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP